Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$27.24 – $36.65
100% from low
Exchange
NASDAQ
ETF
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| HRTSTema Cardiovascular and Metabolic ETF | $36.63 | +1.19% | $52M | — |
| AHLTAmerican Beacon Select Funds - Ahl Liquid Trend ETF | $28.54 | +0.37% | $48M | — |
| FMETFidelity Metaverse ETF | $36.44 | +2.32% | $49M | — |
| FTWOStrive Natural Resources and Security ETF | $43.31 | -0.23% | $57M | — |
| ITDDiShares LifePath Target Date 2040 ETF |
No company description on file.
No one on the platform currently holds HRTS.
No tracked institution reports a position in HRTS as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-12-10 | $0.4729 | 2025-12-11 |
| 2024-12-11 | $0.4693 | 2024-12-12 |
No one on the platform has traded HRTS yet.
| $38.42 |
| +0.81% |
| $102M |
| — |
| KDEFPLUS Korea Defense Industry Index ETF | $41.24 | +5.88% | $41M | — |
| NDIAGlobal X - India Active ETF | $27.20 | -0.14% | $59M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Why Did BCDA Stock Surge More Than 50% Today? $BCDA $HRTS https://stocktwits.com/news/equity/markets/why-did-bcda-stock-surge-more-than-50-today/cZ0FYVtReCj
View on StockTwits ↗$HRTS Current Stock Price: $35.87 Contracts to trade: $30.0 HRTS Mar 20 2026 Call Entry: $1.45 Exit: $2.79 ROI: 92% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$HRTS Current Stock Price: $35.49 Contracts to trade: $30 HRTS Mar 20 2026 Call Entry: $1.45 Exit: $1.84 ROI: 27% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$HRTS Macro trends are relevant, yet internal execution remains the decisive catalyst. Margins must remain resilient as activity scales. Guidance slippage would be magnified by the market. Future returns will be dictated by execution quality, not headlines.
View on StockTwits ↗$HRTS Current Stock Price: $34.32 Contracts to trade: $30 HRTS Mar 20 2026 Call Entry: $1.45 Exit: $2.87 ROI: 98% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen' $HRTS $NVO https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41025381/exclusive-novo-nordisk-faces-political-heat-over-weight-loss-drug-prices-ahead-of-e
View on StockTwits ↗Added to my watchlist going to keep an eye on this one, thanks for shouting this out !! $HRTS
View on StockTwits ↗$HRTS Just read the Benzinga article, I had no idea of this ETF’s existence prior. Lotsa fatsos around, I think GLP-1 is here to stay.
View on StockTwits ↗Analyst raising annual global sales forecasts for obesity treatments to about $150B by the early 2030s vs top sales ests were in the $100B range a year ago. Analysts cite recent data showing the self-injected drugs help stave off costly emergencies like heart attack and stroke or treat chronic conditions like sleep apnea, supporting the case for employers and insurers to pay for them. Global spending on obesity medications totaled $24B last year That +27% annual growth estimate compares with a prior projection of +13%. Supplies of both $NVS Wegovy & $LLY Zepbound remain constrained, but the companies have been increasing production. In the US 40% of adults are obese & another 30% are overweight. Worldwide adult obesity rate has more than doubled since 1990 - over a billion people globally. Over 80 experimental obesity drugs have reached the human testing stage but the bull case is that access will widen & higher volume will offset price erosion. $VKTX $AMGN $HRTS
View on StockTwits ↗$ATYR $HRTS New Options Listings courtesy @marketchameleonwins
View on StockTwits ↗Two dominant investing themes over the past year have been AI and weight-loss drugs. Neena Mishra focuses on weight loss ETFs. $HRTS https://www.zacks.com/stock/news/2283455/etfs-to-profit-from-the-weight-loss-drug-boom
View on StockTwits ↗$THNR $OZEM $HRTS $LLY $NVO The $THNR Weight Loss ETF has won the performance battle in its first week out. 🏆
View on StockTwits ↗Following two late-stage clinical trials from Eli Lilly ($LLY), its weight loss treatment Zepbound showed potential to treat patients dealing with sleep apnea. Investment partner David Song shares, “The data are solid enough that the overhangs on these stocks will remain.” Read his full insights on MarketWatch (tag): https://www.marketwatch.com/story/eli-lilly-reports-positive-data-in-phase-3-trial-of-weight-loss-drug-as-treatment-for-sleep-apnea-0d9f8591 $HRTS $LLY
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.